Emergent Biosolutions (EBS) Misses Q4 EPS by 1c; Issues Mixed Outlook
Emergent Biosolutions (NYSE: EBS) reported Q4 EPS of $0.44, $0.01 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $94.6 million versus the consensus estimate of $95.09 million.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Emergent Biosolutions sees FY2013 revenue of $40-50 million, versus the consensus of $60 million.
Emergent Biosolutions sees FY2013 revenue of $290-310 million, versus the consensus of $300.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.